Aptinyx (APTX) Raised to Buy at Zacks Investment Research

Aptinyx logo Aptinyx (NASDAQ:APTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The firm currently has a $6.00 price target on the stock. Zacks Investment Research ‘s target price would indicate a potential upside of 14.50% from the company’s current price.

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “

A number of other equities analysts have also weighed in on APTX. Leerink Swann decreased their price target on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday. JPMorgan Chase & Co. lowered shares of Aptinyx from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $30.00 to $8.00 in a report on Thursday. BMO Capital Markets decreased their price target on shares of Aptinyx to $18.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Cantor Fitzgerald assumed coverage on shares of Aptinyx in a report on Wednesday, November 14th. They issued an “overweight” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Aptinyx presently has a consensus rating of “Buy” and an average target price of $18.80.

APTX stock traded down $0.15 during midday trading on Monday, hitting $5.24. The stock had a trading volume of 674,726 shares, compared to its average volume of 563,517. Aptinyx has a 12-month low of $4.70 and a 12-month high of $32.25.

Aptinyx (NASDAQ:APTX) last released its earnings results on Tuesday, November 13th. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.01) by $0.58. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $1.10 million. As a group, sell-side analysts expect that Aptinyx will post -2.33 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in APTX. BlackRock Inc. acquired a new position in shares of Aptinyx in the 2nd quarter valued at $967,000. Point72 Asset Management L.P. acquired a new position in shares of Aptinyx during the 2nd quarter valued at $725,000. Millennium Management LLC acquired a new position in shares of Aptinyx during the 2nd quarter valued at $2,615,000. Northern Trust Corp acquired a new position in shares of Aptinyx during the 2nd quarter valued at $304,000. Finally, Strs Ohio acquired a new position in shares of Aptinyx during the 3rd quarter valued at $110,000. Institutional investors own 64.76% of the company’s stock.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Story: LIBOR

For more information about research offerings from Zacks Investment Research, visit Zacks.com Analyst Recommendations for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *